A targeting vector was designed with a minimal adenovirus type 2 major late splice acceptor, a loxP-flanked Neo-STOP cassette, a cDNA sequence encoding human GNAQ* (a mutant form of GNAQ rendered constitutively active by substitution of Glutamine 209 for Leucine (Q209L), and a bovine growth hormone polyadenylation signal.